Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 28;4(1):67-78.
doi: 10.1007/s40121-015-0058-x. Online ahead of print.

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients

Nimish Patel  1 , Mona Nasiri, Arden Koroglu, Steven Bliss, Melissa Davis, Louise-Anne McNutt, Christopher Miller
Affiliations

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients

Nimish Patel et al. Infect Dis Ther. .

Abstract

Introduction: This study compares the expected occurrence of contraindicated drug-drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to quantify, in relative terms, the population-based risk of XDDIs. Second, this study identified the predictors of XDDIs when HCV therapies are added to medication profiles.

Methods: A cross-sectional study was performed among Veterans' Affairs patients. Inclusion criteria were: (1) age ≥18 years, (2) HCV infection, and (3) availability of a medication list. Patients with human immunodeficiency virus were excluded. Demographics, comorbidities, year of HCV diagnosis, and most recent medication list were collected from medical records. The primary outcome was the presence of XDDIs involving HCV therapy and the medications in the patient's home medication list after the addition of either SIM- or SOF-containing regimens. To define XDDIs, Lexi-Interact drug interaction software was used.

Results: 4,251 patients were included. The prevalence of XDDIs involving SIM- or SOF-containing therapy were 12.6% and 4.7% (p < 0.001), respectively. In multivariable analyses examining the predictors of XDDIs involving SIM-containing therapy, the only medication-related predictor was use of ≥6 home medications (odds ratio OR 4.58, 95% confidence interval CI 3.54-5.20, p < 0.001). Similarly, use of ≥6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57-5.70, p < 0.001).

Conclusions: Sofosbuvir-containing therapy had a lower frequency of XDDIs than SIM-containing therapy. Polypharmacy with various classes of home medications predicted XDDIs involving SIM- or SOF-containing therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Prevalence of contraindicated drug–drug interactions (XDDI) involving hepatitis C therapy after addition of simeprevir- and sofosbuvir-containing therapy
See this image and copyright information in PMC

References

    1. Olysio (simeprevir) tablet package insert. Titusville: Janssen Therapeutics, Division of Janssen Products, LP; 2013.
    1. Sovaldi (sofosbuvir) package insert. Foster City: Gilead Sciences; 2013.
    1. Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases/Infectious Diseases Society of America, with International Antiviral Society–USA. http://www.hcvguidelines.org/full-report-view. Accessed Sept 1, 2014.
    1. Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447–453. doi: 10.1111/jgs.12695. - DOI - PMC - PubMed
    1. Centers for Disease Control & Prevention. Division of Viral Hepatitis. Surveillance for Viral Hepatitis—United States, 2011. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/index.htm. Accessed Sept 1, 2014.